EC Approves Bristol-Myers Squibb's Empliciti Treatment for Certain Myeloma Patients

   By Stephen Nakrosis 
 

Bristol-Myers Squibb Co. (BMY) on Tuesday said the European Commission has approved the use of Empliciti, or elotuzumab, in combination for some patients with multiple myeloma.

The drugmaker said the approval was for Empliciti Plus Pomalidomide and Low-Dose Dexamethasone, or EPd, to treat patients with relapsed and refractory multiple myeloma.

According to the company, the "median progression-free survival and overall response rate doubled among patients receiving EPd compared to pomalidomide and low-dose dexamethasone alone."

This is the second Empliciti-based combination approved in Europe for those patients, the company said.

Bristol-Myers Squibb said the U.S. Food and Drug Administration approved this combination to treat adult patients with multiple myeloma who have received at least two prior therapies in November of last year.

Bristol-Myers Squibb is co-developing Empliciti with AbbVie Inc. (ABBV). Bristol-Myers Squibb said it is responsible for commercial activities.

--Write to Stephen Nakrosis at [e-mail]

(END) Dow Jones Newswires

August 27, 2019 17:38 ET (21:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.